Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma

Melanoma Research

Volumn 14, Issue 1, 2004, Pages 63-66

  Bedikian, Agop Y ^a   Plager, Carl ^a   Papadopoulos, Nicholas ^a   Eton, Omar ^a   Ellerhorst, Julie ^a   Smith, Theresa ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemotherapy; Melanoma; Paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; CIMETIDINE; CISPLATIN; DACARBAZINE; DEXAMETHASONE; DIPHENHYDRAMINE; INTERFERON; INTERLEUKIN 2; PACLITAXEL; VINBLASTINE;

ADULT; AGED; ANOREXIA; ANXIETY DISORDER; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONFUSION; DRUG HYPERSENSITIVITY; DRUG INFUSION; EDEMA; EPISTAXIS; FATIGUE; FEMALE; FLUSHING; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MENTAL INSTABILITY; METASTASIS; MUSCLE SPASM; NAUSEA; ONYCHOLYSIS; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TASTE DISORDER; TREATMENT OUTCOME; VISUAL IMPAIRMENT; VOMITING; WHEEZING;

EID: 1642265257     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200402000-00010     Document Type: Article

References (25)

1. Anderson CM, Buzaid AC, Legha SS. Systemic treatments for advanced cutaneous melanoma. Oncology 1995; 9:1149-1158.
2. Bedikian AY, Legha SS, Mavligit G, Carrasco CH, Khorana S, Plager C, et al. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center Experience and prognostic factors. Cancer 1995; 76:1665-1670.
3. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990; 82:1247-1259.
4. Weirnik PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP. Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 1987; 5:1232-1239.
5. Pazdur R, Kudelka AP, Kavanagh JJ, Cohen PR, Raber MN. The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treatment Reviews 1993; 19:351-386.
6. Einzig Al, Wiernik PH, Tenteromano L, Benson L, Tan V, Kaplan J. Phase I study of Taxol and G-CSF in patients with unresectable malignancy. Proc Am Soc Clin Oncol 1994; 13:401.
7. Legha SS, Ring S, Papadopoulos N, Raber M, Benjamin RS. A phase II trial of taxol in metastatic melanoma. Cancer 1990; 11:2478-2481.
8. Helson L, Helson C, Malik S, Pilia P. Paclitaxel effects on human glial and neuroblastoma, primitive neuroectodermal tumor, melanoma, and glioblastoma cell lines. Proc Am Soc Clin Oncol 1993; 12:143(abstract 370).
9. Helson C, He L, Braverman S, Pilia P, Helson L. Schedule dependency of paclitaxel tissue distribution and anti-tumor activity in nude mice with neuroblastoma. Proc Am Assoc Cancer Res 1994; 35:424(abstract 2527).
10. Helson L, Helson C. Rationale for a Q 4 D schedule for paclitaxel. Proc Am Assoc Cancer Res 1994; 35:340(abstract 2026).
11. Helson L, Puccio M, Ostrow S, Mittelman A, Ahmed T. Phase I paclitaxel: fractionated Q 4 D brief infusional schedule in advanced solid tumors. Proc Am Soc Clin Oncol 1994; 13:163(abstract 448).
12. Feldman E, Seiter K, Helson L, Traganos F, Gaston K, Romero MB, et al. Phase I evaluation of a short infusion every 4 day schedule of paclitaxel in refractory acute leukemia. Proc Am Soc Clin Oncol 1994; 13:311 (abstract 1022).
13. Donfrancesco A, Deb G, Sio L, Habetswallner, Helson L Phase I trial of a q 4 day paclitaxel regimen in pediatric patients with recurrent solid tumors. Proc Am Soc Clin Oncol 1994; 13:426(abstract 1463).
14. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10:1-10.
15. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991; 83:1797-1805.
16. Huizing MT, Keung AC, Rosing H, van der Kuij V, ten Bokkel Huinink WW, Mandjes IM, et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 1993; 11:2127-2135.
17. Norton L. Adjuvant breast cancer therapy: Current status and future strategies Growth kinetics and the improved drug therapy of breast cancer. Semin Oncol 1999; 26:11-20.
18. Lueftner D, Mergenthaler HG, Gunewald R, Flath B, Budach V, Possinger K. Paclitaxel in a weekly fractionated schedule in advanced breast cancer. Proc Am Soc Clin Oncol 1996; 15:150(abstract 266).
19. Fennelly D, Aghajanian C, Shapiro F, O'Flaherty C, McKenzie M, O'Connor C, et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997; 15:187-192.
20. Akerley W, Glantz M, Choy H, Rege V, Sambandam S, Joseph P, et al. Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol 1998; 16:153-158.
21. Rosenberg P, Andersson H, Boman K, Ridderheim M, Sorbe B, Puistola U, Horvath G. A randomized multicenter study of single agent paclitaxel (Taxol) given weekly versus every three weeks to patients with platinum therapy. Proc Am Soc Clin Oncol 1999; 18:368a(abstract 1420).
22. Greco FA, Thomas M, Hainsworth JD. One-hour paclitaxel infusions: review of safety and efficacy. Cancer J Sci Am 1999; 5:179-191.
23. Brown T, Havlin K, Weiss G, Cagnola J, Koeller J, Kuhn J, et al. A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol 1991; 9:1261-1267.
24. Nathan FE, Berd D, Sato T, Mastrangelo MJ. Paclitaxel and tamoxifen: an active regimen for patients with metastatic melanoma. Cancer 2000; 88:79-87.
25. Zonder JA, LoRusso P, Heilbrun L, Flaherty LE. Phase II trial of weekly paclitaxel as second line treatment of metastatic malignant melanoma (MMM). Proc Am Soc Clin Oncol 2000; 19:571a(abstract 2249).